Safety of Rimegepant, an Oral CGRP Receptor Antagonist, Plus CGRP Monoclonal Antibodies for Migraine

OBJECTIVE: Evaluate the safety and tolerability of oral rimegepant when used for acute treatment concomitantly with a monoclonal antibody (mAb) targeting the calcitonin gene‐related peptide (CGRP) ligand or receptor (CGRP mAb) for the preventive treatment of migraine. BACKGROUND: The efficacy of CGR...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Headache
Main Authors: Berman, Gary, Croop, Robert, Kudrow, David, Halverson, Philip, Lovegren, Meghan, Thiry, Alexandra C., Conway, Charles M., Coric, Vladimir, Lipton, Richard B.
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley and Sons Inc. 2020
Assuntos:
Research Submissions
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7496574/
https://ncbi.nlm.nih.gov/pubmed/32799325
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/head.13930
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados